All News

A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

A commentary by FDA officials Vinay Prasad, MD, MPH, and Martin Makary, MD, MPH, details the new system for drug approvals in the US.

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants.

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting weight-management outcomes with data-driven oversight.

A global analysis found that although alopecia areata rates in young adults have modestly declined since 1990, the disease continues to disproportionately affect women and people in their early 30s.

Higher baseline monocyte counts, along with preserved basophils and low C-reactive protein, independently predict complete remission on anti-IgE therapy for CSU.

Data suggest the benefits of zanubrutinib versus acalabrutinib in R/R chronic lymphocytic leukemia were even more pronounced in high-risk cases.

The number of brick and mortar abortion clinics in the US fell between 2024 and 2025, with notable closures even in states considered key access points.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes.

Patients with heart failure tended to have lower treatment intensity at hospital admission, but their cardiac load improved as blood pressure treatment intensified.

Medicare Advantage beneficiaries face forced disenrollment in 2026 as plan exits drive coverage termination, pushing millions toward traditional Medicare and Part D’s $2100 cap.

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date.

Learn what sickle cell disease is, who it affects most, today’s treatment options, and how cost and inequities limit access.

Systematic review finds sleep disturbances in menopause are highly prevalent and linked to worse QOL, depression, pain, and reduced work productivity.

A new Mayo Clinic study questions the benefit of implantable cardioverter-defibrillator use to treat patients with transthyretin cardiac amyloidosis.

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions.

Patients with myasthenia gravis (MG) had greater morbidity and extended hospitalization when they underwent cardiac surgery.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Advances in sickle cell therapies, including gene editing, offer hope—but racial disparities, cost, and access barriers remain major challenges.

Today's approval enables once-monthly SC amivantamab dosing for patients with EGFR-mutant NSCLC, reducing clinic visits without compromising efficacy or safety.

New bipartisan legislation extends key health care programs and tightens oversight of PBMs in Medicare Part D and commercial markets, but impacts on drug costs will not be immediate.

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers.

Oral GLP-1 costs, insurance gaps, and formulary switches reshape drug pricing and access—learn how to navigate coverage.